Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.

Anticancer research - 1 Oct 2024

Kim Insu, Choi Sun Ha, Lee Shin Yup, Yoo Seung Soo, Park Ji Eun, Shin Kyeong-Cheol, Jang Jong Geol, Hong Kyung Soo, Kwon Yong Shik, Park Sun Hyo, Choi Keum-Ju, Jung Chi Young, Kim Mi-Hyun, Kim Soo Han, Seol Hee Yun, Kim Jehun, Park Jin-Han, Kim Tae Hoon, Eom Jung Seop, Ahn June Hong

Abstract excerpt

BACKGROUND/AIM: Durvalumab consolidation is less effective in patients with epidermal growth factor receptor mutant (EGFR M+) NSCLC. Studies of durvalumab on EGFR M+ NSCLC as an expression of programmed death-ligand 1 (PD-L1) expression are limited. The purpose of this study was to determine the effect of durvalumab on PD-L1 expression in EGFR M+ patients. PATIENTS AND METHODS: This study included 249...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Neoplasm Staging

Share to Progression-Free Survival

Source

Identifiers

PMID: 39348962
DOI: 10.21873/anticanres.17279

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.PMID 39348962Read ↗

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.Semantic proximity Read ↗

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.Semantic proximity Read ↗

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancersSemantic proximity Read ↗

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.Semantic proximity Read ↗

Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT RadiomicsSemantic proximity Read ↗

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 studySemantic proximity Read ↗

Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.Semantic proximity Read ↗

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCSemantic proximity Read ↗

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumabSemantic proximity Read ↗

Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.